CN104903314B - 1-[1-(苯甲酰基)-吡咯烷-2-羰基]-吡咯烷-2-甲腈衍生物 - Google Patents

1-[1-(苯甲酰基)-吡咯烷-2-羰基]-吡咯烷-2-甲腈衍生物 Download PDF

Info

Publication number
CN104903314B
CN104903314B CN201380059126.XA CN201380059126A CN104903314B CN 104903314 B CN104903314 B CN 104903314B CN 201380059126 A CN201380059126 A CN 201380059126A CN 104903314 B CN104903314 B CN 104903314B
Authority
CN
China
Prior art keywords
pyrrolidine
carbonyl
carbonitrile
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380059126.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104903314A (zh
Inventor
埃内斯特·希拉尔特列多
特里萨·塔拉戈克卢瓦
罗格·普拉德斯科萨诺
索莱达·罗约格拉西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biological Medicine Warf Mechanism (irb Barcelona)
Universitat de Barcelona UB
Accure Therapeutics SL
Original Assignee
Biological Medicine Warf Mechanism (irb Barcelona)
Universitat de Barcelona UB
IProteos SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biological Medicine Warf Mechanism (irb Barcelona), Universitat de Barcelona UB, IProteos SL filed Critical Biological Medicine Warf Mechanism (irb Barcelona)
Publication of CN104903314A publication Critical patent/CN104903314A/zh
Application granted granted Critical
Publication of CN104903314B publication Critical patent/CN104903314B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Epidemiology (AREA)
CN201380059126.XA 2012-11-12 2013-11-11 1-[1-(苯甲酰基)-吡咯烷-2-羰基]-吡咯烷-2-甲腈衍生物 Active CN104903314B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382446.8 2012-11-12
EP12382446.8A EP2730571A1 (en) 2012-11-12 2012-11-12 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
PCT/EP2013/073460 WO2014072498A1 (en) 2012-11-12 2013-11-11 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Publications (2)

Publication Number Publication Date
CN104903314A CN104903314A (zh) 2015-09-09
CN104903314B true CN104903314B (zh) 2018-06-05

Family

ID=47278735

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380059126.XA Active CN104903314B (zh) 2012-11-12 2013-11-11 1-[1-(苯甲酰基)-吡咯烷-2-羰基]-吡咯烷-2-甲腈衍生物

Country Status (25)

Country Link
US (2) US10125097B2 (https=)
EP (2) EP2730571A1 (https=)
JP (1) JP6203278B2 (https=)
KR (1) KR102151290B1 (https=)
CN (1) CN104903314B (https=)
AU (1) AU2013343430B2 (https=)
BR (1) BR112015010377A8 (https=)
CA (1) CA2890042C (https=)
CY (1) CY1118818T1 (https=)
DK (1) DK2917209T3 (https=)
EA (1) EA028422B1 (https=)
ES (1) ES2621672T3 (https=)
HR (1) HRP20170485T1 (https=)
HU (1) HUE032472T2 (https=)
LT (1) LT2917209T (https=)
ME (1) ME02706B (https=)
MX (1) MX367488B (https=)
NZ (1) NZ709096A (https=)
PL (1) PL2917209T3 (https=)
PT (1) PT2917209T (https=)
RS (1) RS55865B1 (https=)
SI (1) SI2917209T1 (https=)
SM (1) SMT201700202T1 (https=)
WO (1) WO2014072498A1 (https=)
ZA (1) ZA201504269B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2730571A1 (en) 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
EP3031458A1 (en) * 2014-12-09 2016-06-15 Iproteos S.L. Use of 1-[(2-phenylcycloprop-1-yl)carbonyl]-2-[(1,3-thiazolidin-3-yl)carbonyl]perhydroindole in the treatment of schizophrenia-associated cognitive deficits
JP2021506972A (ja) 2017-12-15 2021-02-22 プラクシス バイオテック エルエルシー 線維芽細胞活性化タンパク質の阻害剤
CN113811529A (zh) 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂
BR112023000335A2 (pt) * 2020-07-07 2023-01-31 Accure Therapeutics S L 1-[1-(4-benzilóxi-3,5-diflúor-benzoil)-4-flúor-pirrolidina-2-carbonil]-pirrolidina-2-carbonitrila
MY208099A (en) 2020-12-28 2025-04-15 Sarawak Biodiversity Council Compound for treating neurodegenerative diseases and its isolation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004468A1 (en) * 2001-07-04 2003-01-16 Orion Corporation Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use
CN1747930A (zh) * 2003-01-03 2006-03-15 奥赖恩公司 具有脯氨酰基寡肽酶抑制活性的化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018891A1 (en) * 1990-06-04 1991-12-12 Pfizer Inc. Aromatic pyrrolidine and thiazolidine amides
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
HUT76640A (en) * 1995-08-17 1997-10-28 Chinoin Gyogyszer Es Vegyeszet Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use
DE19603510A1 (de) 1996-02-01 1997-08-07 Knoell Hans Forschung Ev Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase
MXPA03000223A (es) * 2000-07-19 2003-06-06 Hoffmann La Roche Derivados de pirrolidina como inhibidores de la enzima conversor de endotelina.
FI20031018A0 (fi) 2003-07-04 2003-07-04 Orion Corp Parannus aivovammasta toipumiseen
JP4630192B2 (ja) 2003-09-24 2011-02-09 日本化薬株式会社 プロリルオリゴペプチダーゼ阻害剤
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
ES2302473B1 (es) 2006-12-22 2009-06-12 Universidad De Barcelona Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos.
WO2010083570A1 (en) * 2009-01-23 2010-07-29 The University Of Sydney Novel metabolic disease therapy
EP2730571A1 (en) 2012-11-12 2014-05-14 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004468A1 (en) * 2001-07-04 2003-01-16 Orion Corporation Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use
CN1747930A (zh) * 2003-01-03 2006-03-15 奥赖恩公司 具有脯氨酰基寡肽酶抑制活性的化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Heihachiro Arai et al.."Synthesis of Prolyl Endopeptidase Inhibitors and Evaluation of Their Structure-Activity Relationships;In Vitro Inhibition of Prolyl Endopeptidase from Canine Brain.《Chem. Pharm. Bull》.1993,第41卷(第9期),第1583-1588页. *

Also Published As

Publication number Publication date
US10611727B2 (en) 2020-04-07
CA2890042C (en) 2021-06-01
DK2917209T3 (en) 2017-04-18
CN104903314A (zh) 2015-09-09
US20190084927A1 (en) 2019-03-21
SI2917209T1 (sl) 2017-05-31
CY1118818T1 (el) 2018-01-10
LT2917209T (lt) 2017-04-25
PT2917209T (pt) 2017-03-31
HK1214597A1 (en) 2016-07-29
JP6203278B2 (ja) 2017-09-27
EA201590942A1 (ru) 2015-10-30
MX2015005931A (es) 2016-02-05
ME02706B (me) 2017-10-20
EP2917209B1 (en) 2017-02-08
MX367488B (es) 2019-08-20
AU2013343430B2 (en) 2017-05-25
WO2014072498A1 (en) 2014-05-15
ZA201504269B (en) 2016-09-28
US20160168088A1 (en) 2016-06-16
AU2013343430A1 (en) 2015-07-02
BR112015010377A2 (pt) 2017-07-11
PL2917209T3 (pl) 2017-09-29
EP2917209A1 (en) 2015-09-16
SMT201700202T1 (it) 2017-05-08
EP2730571A1 (en) 2014-05-14
NZ709096A (en) 2018-04-27
HUE032472T2 (en) 2017-10-30
US10125097B2 (en) 2018-11-13
EA028422B1 (ru) 2017-11-30
HRP20170485T1 (hr) 2017-06-02
CA2890042A1 (en) 2014-05-15
KR20150082634A (ko) 2015-07-15
JP2015536965A (ja) 2015-12-24
ES2621672T3 (es) 2017-07-04
KR102151290B1 (ko) 2020-09-03
RS55865B1 (sr) 2017-08-31
BR112015010377A8 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
US10611727B2 (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
KR20160116018A (ko) 보체 매개 질환의 치료를 위한 아미드 화합물
NZ522823A (en) Substituted imidazoles as TAFIa inhibitors
US20140045771A1 (en) Novel dipeptidyl peptidase iv (dp-iv) compounds
TWI893162B (zh) 1-[1-(4-苄氧基-3,5-二氟-苯甲醯)-4-氟-吡咯烷-2-羰基]-吡咯烷-2-腈
RU2841064C1 (ru) 1-[1-(4-бензилокси-3,5-дифтор-бензоил)-4-фтор-пирролидин-2-карбонил]-пирролидин-2-карбонитрил
HK1214597B (en) 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives
HK40084881B (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
HK40084881A (en) 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile
CN119451944A (zh) Prep结合配体
HK40081706A (en) N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant